StreetAlpha.app
Home › Stocks › FENC

Fennec Pharmaceuticals Inc. (FENC)

$13.58
▲ +6.43%
LAST CLOSE · NOV 17

Fennec Pharmaceuticals develops and sells PEDMARK, a sodium thiosulfate injection, from Research Triangle Park, North Carolina. It last closed at $13.58 on Nov 17, up 6.43% on the day. The average 12-month price target from 2 analysts is $17.50 (+28.9% from the last close), with a high of $19.00 and a low of $16.00.

AI Auto Pilots
Is FENC in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$66.4M
+71.1% vs a year ago
Net income
$2.0M
3.1% margin
EPS (diluted)
$0.03
Operating margin
5.6%
$3.7M operating income
Valuation
Market cap
$479.4M
35.3M shares
P/E
452.7
Price over 12 month EPS
Price to sales
7.2
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$48.7M
At Sep 30
Shareholder equity
$49.2M
Shares outstanding
35.3M
At Nov 10
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: $1.5M$1.5MFY2022FY2023: $21.3M$21.3MFY2023FY2024: $47.5M$47.5MFY2024FY2025: $44.6M$44.6MFY2025

From FENC's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated FENC in the past 90 days, not enough for a consensus
Average 12-month target
$17.50
▲ 28.9% upside

Based on 2 analysts who set a price target on FENC in the past 90 days. The average target is $17.50, with a high of $19.00 and a low of $16.00, compared with the last close of $13.58.

Low $16.00Avg $17.50High $19.00
Blue marker: last close $13.58
Highest target$19.00
Average target$17.50
Lowest target$16.00
Latest rating changes
B. Riley SecuritiesTarget raised
Nov 16Buy$18 → $19
HC Wainwright & Co.Reiterated
Sep 9Buy$16
B. Riley SecuritiesReiterated
Aug 12Buy$18
WedbushMaintained
Aug 12Buy$16
HC Wainwright & Co.Maintained
May 22Buy$16
DateFirmActionRatingPrice target
Nov 16B. Riley SecuritiesTarget raisedBuy$18 → $19
Sep 9HC Wainwright & Co.ReiteratedBuy$16
Aug 12B. Riley SecuritiesReiteratedBuy$18
Aug 12WedbushMaintainedBuy$16
May 22HC Wainwright & Co.MaintainedBuy$16
Loading…

Technical Analysis

FENC · as of the Nov 17 close · updated after every close
Uptrend, overbought

The stock is 21% above its 20 day and 21% above its 50 day average. It is 31% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 73), overbought. The nearest support is the Pivot at $13.27, and the nearest resistance the 52 week high at $13.63.

Short trendBullish
Long trendBullish
MomentumStrong
StretchOverbought
VolatilityHigh, 5.7%/day
Key levels
$13.94Pivot R1+2.7%
$13.6352 week high+0.4%
$13.58Last close
$13.27Pivot−2.3%
$12.91Pivot S1−4.9%
$10.88Swing low (Aug 24)−19.9%
$10.86100 day average−20.0%
$10.7720 day average−20.7%
$10.6750 day average−21.4%
$9.41200 day average−30.7%
$5.6552 week low−58.4%
Indicators
RSI (14)72.84Overbought above 70Overbought
MACD0.44Above its signal lineBullish
Stochastic92.8Near the top of its rangeOverbought
ADX (14)19.9No clear trend
Williams %R-1.1Oversold below −80, overbought above −20Overbought
CCI (20)302.4Oversold below −100, overbought above 100Overbought
Rate of change+26.9%Change over 10 sessionsBullish
ATR (14)$0.77Typical daily range, 5.7% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for FENC

What happened before

See how FENC did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow FENC usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How FENC has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in FENC in the last 90 days.

Loading…

See today’s whale options flow across the market →

FENC Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲57 buying vs 39 selling
  • ▲Held by funds +4.7 pts
  • ▲Funds holding +14
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding119105+13.3%
In funds' top 10440.0%
Held by funds50.9%46.2%+4.7 pts
New / increased22 / 3525 / 44−17.4%
Reduced / sold out31 / 818 / 8+50.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See FENC institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether FENC is in one of them and how their past FENC trades turned out.

FENC in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered FENC in an article yet. Here's the latest on the wider market.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals is a pharmaceutical company based in Research Triangle Park, North Carolina. Its main product is PEDMARK, a sodium thiosulfate injection that the company develops and commercializes. The company relies on patents and licensed intellectual property to protect PEDMARK from competing generic versions. It works with licensors and collaborators on its technologies and product.

Headquarters
Research Triangle Park, NC